Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

por Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J
Publicado 2010

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer

por Michael, M, Price, T, Ngan, S Y, Ganju, V, Strickland, A H, Muller, A, Khamly, K, Milner, A D, Dilulio, J, Matera, A, Zalcberg, J R, Leong, T
Publicado 2009

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

por Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J
Publicado 2013

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

por Peeters, M, Strickland, A H, Lichinitser, M, Suresh, A V S, Manikhas, G, Shapiro, J, Rogowski, W, Huang, X, Wu, B, Warner, D, Jain, R, Tebbutt, N C
Publicado 2013

Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide

por Cebon, J, Findlay, M, Hargreaves, C, Stockler, M, Thompson, P, Boyer, M, Roberts, S, Poon, A, Scott, A M, Kalff, V, Garas, G, Dowling, A, Crawford, D, Ring, J, Basser, R, Strickland, A, Macdonald, G, Green, M, Nowak, A, Dickman, B, Dhillon, H, Gebski, V
Publicado 2007